Ifosfamide, epirubicin and cisplatin (IEP): another active combination for small cell lung cancer (SCLC)
Sixty-four SCLC patients (44 males and 20 females, median age 60 years, median PS 60%) were treated with an IEP regimen. Forty-nine cases were evaluable, 35 cases were limited disease (LD) and 14 cases were extensive disease (ED). Treatment consisted of ifosfamide 1.5 g/m2 i.v. infusion for 4 h on d...
Saved in:
Main Authors: | Thongprasert S., Jiamsriponges K. |
---|---|
Format: | Article |
Language: | English |
Published: |
2014
|
Online Access: | http://www.ncbi.nlm.nih.gov/pubmed/3502482 http://cmuir.cmu.ac.th/handle/6653943832/3518 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Institution: | Chiang Mai University |
Language: | English |
Similar Items
-
Phase II study of three days' fractionated dosage of ifosfamide, epirubicin and cisplatin in small cell lung cancer
by: Thongprasert S., et al.
Published: (2014) -
Phase II study of ifosfamide, carboplatin, etoposide and GM-CSF in small cell lung cancer
by: Thongprasert S.
Published: (2014) -
Phase II study of paclitaxel (Taxol) and ifosfamide (Holoxan) in inoperable non-small-cell lung cancer
by: Thongprasert S.
Published: (2014) -
Combination of gemcitabine and cisplatin in advanced non-small cell lung cancer
by: Thongprasert S., et al.
Published: (2014) -
Phase II study of cisplatin combined to irinotecan administered alternatingly with docetaxel in advanced non-small cell lung cancer
by: Charoentum C., et al.
Published: (2014)